Candidate MicroRNA biomarkers of therapeutic response to sunitinib in metastatic renal cell carcinoma: A validation study in patients with extremely good and poor response

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10381497" target="_blank" >RIV/00216208:11110/18:10381497 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/18:10381497 RIV/00179906:_____/18:10381497 RIV/00669806:_____/18:10381497 RIV/00216224:14740/18:00106955 and 2 more

Result on the web

<a href="https://doi.org/10.21873/anticanres.12546" target="_blank" >https://doi.org/10.21873/anticanres.12546</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12546" target="_blank" >10.21873/anticanres.12546</a>

Result language

angličtina

Original language name

Candidate MicroRNA biomarkers of therapeutic response to sunitinib in metastatic renal cell carcinoma: A validation study in patients with extremely good and poor response

Original language description

Background/Aim: Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy. Materials and Methods: Based on a literature search, 10 miRNAs were chosen from six relevant studies as candidates for validation: miR-155, miR-484, miR-221, miR-222, miR-425, miR-133, miR-410, miR-141, miR-628 and miR-942. Validation of these miRNAs was performed on cohort of 56 patients with mRCC with extremely good or poor response responses to sunitinib treatment using quantitative reverse transcription-polymerase chain reaction. Patients were divided into either responding (n=24) or non-responding (n=32) groups to sunitinib treatment according to Response Evaluation Criteria in Solid Tumors and progression-free survival (PFS). All patients in the responding group had PFS longer than 18 months, PFS of non-responders was shorter than 6 months in all cases. Results: miR-942 and miR-133 were confirmed as being differentially expressed in tumors of responding and non-responding patients. It was not possible to validate the predictive value of other tested miRNAs, however, expression of miR-221 and miR-425 tended to be positively associated with therapeutic response (p&lt;0.1). We further developed a model based on the combination of miR-942 and miR-133 expression, that enabled identification of non-responding patients with mRCC with sensitivity of 78% and specificity of 79% (area under the curve=0.8071). Conclusion: Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC. (C) 2018 International Institute of Anticancer Research. All rights reserved.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV15-34678A" target="_blank" >NV15-34678A: Prognostic and predictive molecular factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

38

Issue of the periodical within the volume

5

Country of publishing house

GR - GREECE

Number of pages

5

Pages from-to

2961-2965

UT code for WoS article

000449923200046

EID of the result in the Scopus database

2-s2.0-85046512988